Introduction
Glioblastoma (GBM) is a refractory malignancy, with a median survival of only 15-16 months [1, 2] , despite multimodality treatment including surgical resection, external beam radiation therapy and chemotherapy. Most patients will develop recurrent disease after completing initial therapy. Use of the VEGF targeting antibody bevacizumab still represents the mainstay of systemic treatment for recurrent disease in the US [3] , but overall survival (OS) remains poor. Following progression on a bevacizumab containing regimen, no agent has demonstrated significant activity and prognosis remains uniformly dismal [4] [5] [6] . In the recently completed randomized phase III CABARET trial, median OS after progression on bevacizumab was only 3-4 months, independent of bevacizumab continuation [7] . Therefore, there is an urgent need to develop novel therapeutic strategies for patients with recurrent GBM, including the clinically challenging setting of bevacizumab failure.
Alisertib (MLN8237) is an aurora A kinase (AURKA) inhibitor with improved potency and selectivity as compared to earlier inhibitors such as MLN8054 [8] . In experimental models and in patients, alisertib inhibits proliferation of tumor cell lines and induces characteristic pharmacodynamic changes consistent with AURKA inhibition-increased mitotic index, reduced bipolar Abstract Aurora A kinase (AURKA), a member of the serine/threonine kinase family, plays a critical role in cell division, and it is widely overexpressed in a variety of tumors including glioblastoma (GBM). Alisertib (MLN8237) is an orally administered selective AURKA inhibitor with potent antiproliferative activity, currently undergoing clinical testing in different tumor types. In vitro evaluation of alisertib against the primary GBM lines, GBM6, GBM10, GBM12 and GBM39 showed significant antitumor activity with IC 50s ranging between 30 and 95 nM. Orthotopic xenografts of GBM10 and the bevacizumab resistant lines GBM6 and GBM39 were established by implantating 3 × 10 5 cells in the caudate nucleus of nude mice; animals were randomized to treatment with either alisertib 30 mg/kg/day or vehicle. In all three models, treatment with alisertib resulted in a statistically significant prolongation of survival (p < 0.0001). In addition, alisertib administration in these mice decreased phosphorylated aurora-A, induced mitotic arrest and significantly decreased histone H3 phosphorylation in tumors. In conclusion,
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spindles, and increased chromosome alignment abnormalities [8] [9] [10] . Moreover, alisertib has demonstrated antitumor activity against multiple xenograft or disseminated tumor models with dramatic growth inhibition seen in lung (H460:91%) and colon (HCT-116:93%) models [8] . Alisertib's activity against primary brain tumors in vitro and in vivo has not been fully explored to date, however.
Emerging data supports a role for AURKA in glioma oncogenesis. The AURKA gene was amplified in 26 % of gliomas and mRNA overexpression was identified in 60 % of the specimens [11, 12] . These initial studies suggested a possible correlation between the level of AURKA expression and glioma grade, with higher levels observed in GBM. Multiple studies evaluating either AURKA mRNA or protein levels [13] [14] [15] have confirmed this observation, supporting possible associations of AURKA expression in glioma with outcome. Recently published data also implicates AURKA in the self-renewal and tumorigenicity of glioma-initiating cells that contribute to GBM recurrence and treatment resistance [16] .
In vitro data also corroborate the importance of AURKA to GBM growth as thesmallmolecule AURKA inhibitor C1368 was cytotoxic when tested against several GBM cell lines [15] . The aurora kinase inhibitor VE-465 also decreased GBM cell viability via a caspase-independent pathway [17] . In addition, the cytotoxicity of alisertib was tested in a variety of low-passage primary GBM cell lines using a colony formation assay. Alisertib was cytotoxic with IC 50s ranging from 60 to 225 nM. Longer drug exposure times were also associated with enhanced cytotoxicity [14] . Taken together, these data support that therapeutic development of AURKA inhibitors for GBM patients represents a direction worth pursuing.
In this study, using orthotopic primary human GBM xenograft models, we demonstrated that orally administered alisertib significantly prolongs survival, including two animal models which have demonstrated primary resistance to bevacizumab. Correlative studies confirmed target effects of alisertib on AURKA signaling, which supports effective CNS drug penetration in mice. Based on these data, clinical testing of alisertib in GBM patients is warranted.
Methods

Cell culture
Primary GBM xenograft lines were passaged in the flanks of BALB/c nude mice (Charles River) as previously described [18] . For the in vitro experiments, tumors were excised from the mice, minced and subsequently plated onto flasks in DMEM containing 2.5 % FBS and 1× Penn/ Strep at 37 °C, 5 % CO 2 in a humidified environment.
Following short term expansion, cells were removed with Tryple (Invitrogen) prior to plating in vitro for experiments (DMEM, 10 % FBS, 1× Penn/Strep) or for orthotopic implantation into BALB/c nude mice.
MTT assays
GBM6, GBM10, GBM12 and GBM39 xenograft lines were plated in 96 well plates in DMEM containing 10 %FBS and 1×, penicillin/streptomycin at a density of 10 4 cells per well. Twenty-four hours after plating the cells were exposed to different concentrations of alisertib. Cell proliferation was measured by MTT assay (ATCC, Manassas, VA) at days 1, 2, 3, 7, and 10 post exposure to alisertib and the IC 50 was calculated for each xenograft line, as previously described [19] .
GBM6 and GBM39 flank xenograft model
10
6 GBM6 or GBM39 cells/mouse were mixed 1:2 with Matrigel (BD Biosciences, San Jose, CA) and injected subcutaneously into the flanks of BALB/c nude mice. Upon the establishment of palpable tumors mice were treated with either a placebo or alisertib (30 mg/kg/day) by oral gavage. At pre-specified time points after treatment initiation on day 1 (at 1 h and at 8 h post treatment), day 8 (at 1 and 8 h post treatment), day 14 (at 1 and 8 h post treatment), and day 21 (at 1 and 8 h post treatment) tumors were excised, formalin fixed and paraffin embedded. H&E sections were examined for cell morphology and subsequent sections were used for immunostaining.
Orthotopic tumor models
The effect of treatment with alisertib was examined in orthotopic GBM6, GBM39 and GBM10 xenografts by implanting 3 × 10 5 cells into the right caudate nucleus of BALB/c nude mice as previously described [18] using a small animal stereotactic frame. Starting at 2 weeks post tumor implantation, mice were treated with alisertib (30 mg/kg/day) (10-15 animals per group) or placebo (8-15 animals per group) by oral gavage for 22 days. Animals were euthanized as per IACUC guidelines when they developed neurologic symptoms or lost >10 % of body weight. In a parallel experiment, orthotopic xenograft animals were euthanized at a similar schedule as for the GBM39 flank model and brains embedded in paraffin. H and E sections were examined for cell morphology and additional sections were used for immunohistochemistry. The effect of treatment with bevacizumab in the same orthotopic xenograft models was examined by establishing orthotopic xenografts as described above, followed by treatment by intraperitoneal administration of bevacizumab, 5 mg/kg, two times per week or placebo. Animals were euthanized as per IACUC guidelines when they developed neurologic symptoms or lost >10 % of body weight.
Immunohistochemistry for phospho-histone H3
Five-micron sections deriving from xenograft tumors were deparaffinized in CitriSolv (Fisher, Pittsburgh, PA). Slides were then rehydrated in graded ethanol baths, washed briefly with water and incubated with 0.6 % H 2 O 2 in methanol for 20 min. Sections were washed in 75 % ethanol for 3 min, 50 % ethanol for 3 min and distilled water for 3 min. Sections were placed in Antigen Retrieval Citra (Biogenex, San Ramon, CA) at room temperature followed by a 99 °C water bath for 20 min, and subsequently placed on ice for 20 min prior to being transferred into PBS. Sections were blocked with 10 % Normal Goat Serum (NGS) in PBS containing 0.01 % Triton X-100. Rabbit anti-human p-Histone H3 (Ser 10)-R (Santa Cruz Biotechnology, Inc, Dallas, TX) (add KI67) was diluted 1:250 in PBS containing 10 % NGS, applied to each section at 4 °C overnight in a humidified chamber followed by three brief washes in PBS. Sections were exposed to a goat anti-rabbit IgG-B in PBS containing 10 % NGS for 60 min, developed using the VectaStain Elite and DAB kits as per manufacturer directions (Vector, Burlingame, CA), and counterstained with hematoxylin for 30 s. Photographs were taken using a 40× objective in a Zeiss AxioPlan2 microscope.
Immunohistochemistry for phospho aurora-A
Formalin fixed, paraffin embedded tumor xenografts were sectioned at 5 µm and stained for anti-phospho-aurora A (phospho T288) protein. Antigen was retrieved with the Leica Bond RX stainer (Leica, Buffalo, IL) using Epitope Retrieval Solution 1 (citrate based solution, pH 6). The tissues were incubated in Rodent Block M by Biocare RBM961L for 30 min. Primary anti-phospho-aurora A antibody was diluted in Dako background reducing diluent and incubated for 30 min. Staining was conducted using polymer refine detection kit from Leica that includes DAB per manufacturer's recommendation. Primary anti-phospho-aurora A (phospho T288) antibody (Abcam, ab58494) was used at 1:300 dilutions. A Zeiss Axioplan 2 microscope and Axiovision software (version 4.7) were used to generate images under bright field configured with 20× PlanNEOFLUAR (NA 0.50) and 40× N-ACHROPLAN (NA 0.65). 
Fig. 1 a-c Significant cell killing of primary GBM lines GBM6, GBM10, and GBM39 following exposure to alisertib was demonstrated in vitro by MTT assays
Results
Assessment of therapeutic effect in vitro
In order to determine in vitro activity of alisertib against primary GBM lines, MTT assays were performed to determine the IC 50, by exposing the indicated cells to 0-1 µM of alisertib. IC 50 ranged from 30 to 95 nM (IC 50 GBM39 = 30 nM, IC 50 GBM6 = 37 nM, IC 50 GBM12 = 46 nM, IC 50 GBM10 = 95 nM). Next, primary GBM cells were treated with alisertib at their respective IC 50 , and cell proliferation was monitored over time. Significant in vitro antitumor activity was observed in all cell lines tested (Fig. 1a-c) . Since exposure to alisertib can cause cell senescence with maintenance of low level metabolic activity, the observed significant in vitro activity using the MTT assay could actually represent an underestimation of the effect.
Assessment of therapeutic effect in vivo
In order to assess sensitivity to bevacizumab, an agent commonly used in recurrent GBM treatment, GBM6, GBM10 and GBM39 orthotopic xenografts were treated with bevacizumab versus placebo (ten animals per group). Treatment of GBM10 xenografts with bevacizumab led to significant prolongation of survival (50 vs. 23 days, p < 0.0001). In contrast, there was no difference in GBM39 (25 vs. 24 days, p = 0.9) or GBM6 (43 vs. 45 days, p = 0.12) xenografts, indicating primary resistance to bevacizumab (Fig. 2) . In order to evaluate the in vivo activity of alisertib, orthotopic xenograft tumor models in BALB/c nude mice were established by implanting 3 × 10 5 GBM6, GBM10 or GBM39 glioma cells into the right caudate nucleus and treating for 22 days with alisertib by oral gavage (30 mg/ kg/day) or vehicle control. Significant prolongation of survival was noted in all three models (p < 0.0001) following treatment with alisertib versus vehicle controls (Fig. 3) . 
Histologic findings
Histologic examination of formalin fixed, paraffin embedded tissue sections, obtained at the prespecified euthanasia time points revealed the accumulation of polyploid cells, consistent with aurora A inhibition (Fig. 4a,  b) . Immunohistochemical staining of these sections, in both flank and orthotopic models, demonstrated significant decrease in phospho aurora A staining consistent with target inhibition (Fig. 4c, d ). The similar findings of AURKA target inhibition both in flank and orthotopic models indicate that alisertib can effectively cross the blood-brain barrier in primary glioma tumors, further supporting the translational relevance of these results. Similarly, there was significant decrease in phospho histone-H3 expression in treated tumors, as compared to untreated controls on days 1 (1 and 8 h after alisertib administration), 8, 14 and 21, indicating decrease in tumor mitotic activity/proliferation (Fig. 4e-h ).
Discussion
Aurora serine/threonine kinases are key mitotic regulators required for the maintenance of chromosomal stability [20, 21] by being involved in many steps as cells enter and progress through mitosis. In mammalian cells aurora kinases consist of three members, aurora-A, -B and -C that are expressed in a cell cycle dependent fashion. Aurora-A is localized primarily on centrosomes, spindle poles, and transiently along the spindle microtubules as cell progress through mitosis [21, 22] . Given the critical role of aurora-A in cell mitosis, several small molecule inhibitors have been developed and currently tested clinically [23] . Aurora-A overexpression in high grade gliomas including GBM and its impact on multiple signaling pathways involved in growth differentiation [14, [24] [25] [26] supported the rationale of testing the aurora-A inhibitor alisertib in primary GBM lines and xenografts. Management of recurrent GBM represents an ongoing challenge [27] . Despite a plethora of novel therapeutic agents approved for other malignancies, the paucity of effective agents in recurrent GBM treatment is striking, with bevacizumab being the last such agent such approved in the US in 2010. GBM patients at recurrence have invariably failed temozolomide and radiation; available therapeutic options such as nitrosoureas [28] , or alternative schedules of temozolomide (RESCUE) [29] have demonstrated only modest efficacy. The recently completed EORTC 26101 trial demonstrated an improvement in progression free survival with a bevacizumab/lomustine combination as compared to lomustine, but no OS gain in recurrent GBM patients [30] . Of note, median OS in that trial was only 8-9 months indicating that no major improvements have occurred in the management of recurrent GBM, and again highlighting the need for novel more effective approaches.
The data we present here show significant antitumor activity of alisertib in vitro and in vivo against all three primary glioma lines and xenograft models, including two xenograft models that are resistant to bevacizumab treatment. These data are especially promising given the dismal prognosis of patients who have progressed to bevacizumab with a median OS in a range of 3-4 months in a recently completed randomized phase III trial [7] , independent of bevacizumab treatment continuation. The characteristic morphologic effect of AURKA inhibition with presence of large polyploid cells was observed in treated tumors. In addition, immunohistochemical analysis confirmed inhibition of the target pathway with decrease in phosphoro A staining and decrease in phospho-histone H3, not only in flank, but also orthotopic xenografts: the latter indicates that systemic administration of alisertib can effectively inhibit the AURKA target in the CNS. It is of note, that the patient derived orthotopic xenografts employed in this manuscript have been shown to recapitulate not only the molecular characteristics but also the invasiveness of the patient tumor they derive from [18] , which further supports the translational implications of these data.
Other investigators have demonstrated activity of alisertib against orthotopic models deriving from neurosphere cells with stem cell-like properties, the subpopulation of cells being viewed as the most difficult to eradicate and responsible for recurrence following chemotherapy and radiation [31] . Cell line data also indicates additive or synergistic effect with temozolomide and ionizing radiation [32] . Although in vivo demonstration of synergy with temozolomide and radiation is at this point missing, this represents a direction that also merits further preclinical investigation.
In summary, our preclinical data support the promise of alisertib as a novel therapeutic agent against bevacizumab resistant gliomas; clinical trials testing alisertib in this patient population are warranted. 
